Armata Pharmaceuticals, Inc. 8-K

Summary

Credit, warrant and voting agreement amendments. On 1/23/2026, Armata Pharmaceuticals and Innoviva Strategic Opportunities, a subsidiary of principal shareholder Innoviva, extended the maturity of four credit agreements to 6/1/2027. The parties also extended four warrants and amended the voting agreement’s expiration trigger.

Key Figures

• Credit agreements: maturity extended to 6/1/2027.
• Warrants: expiration extended to 1/26/2031 for warrants covering 1,807,396, 2,692,604, 1,867,912 and 4,285,935 common shares.
• Voting agreement: expires at the earlier of 1/26/2031 or FDA approval of a company product candidate for marketing and commercial distribution.

Investor Takeaways

• FDA approval of a product candidate for marketing and commercial distribution would end the voting agreement before its 1/26/2031 outside date.